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1. Introduction
The term stem cell includes a large class of cells defined by their ability to give rise to vari‐
ous mature progeny while maintaining the capacity to self-renew. Embryonic stem cells
(ESCs) were first isolated from the inner mass of late blastocysts in mice by Sir Martin J.
Evans and Matthew Kaufman (Evans & Kaufman, 1981) and independently by Gail R. Mar‐
tin (Martin, 1981). Later, it became possible to obtain ESCs from non-human primates and
humans. In 1998, James Thomson and his team reported the first successful derivation of hu‐
man ESC lines (Thomson et al., 1998), thus extending the great potential of ESCs by provid‐
ing the opportunity to develop stem cell-based therapies for human disease.
Embryonic stem cells are pluripotent, a term that defines the ability of a cell to differentiate
into cells of all three germ layers. There are different types of mammalian pluripotent stem
cells: embryonic stem cells derived from pre-implantation embryos (Evans & Kaufman,
1981), embryonic carcinoma (EC) cells, the stem cells of testicular tumors (Stevens, 1966;
Evans, 1972), epiblast stem cells (EpiSCs) derived from the late epiblast layer of post-implan‐
tation embryos (Brons et al., 2007), and embryonic germ (EG) cells derived from primordial
germ cells (PGCs) of the post-implantation embryo (Matsui et al., 1992; Stewart et al., 1994).
Besides isolating pluripotent cells from different embryonic tissues, various experimental
methods are available nowadays for inducing pluripotency in vitro. These methods include
cloning by somatic cell nuclear transfer (SCNT), cellular fusion with embryonic stem cells,
the induction of parthenogenesis, and direct reprogramming by addition of reprogramming
transcription factors. SCNT is done by replacing the oocyte genome at metaphase II of meio‐
sis with a somatic cell nucleus. Although somatic cell reprogramming has been achieved in
several mammalian species (Wilmut et al., 1997), this seems to be very difficult to achieve in
humans. Only in 2011 Noggle et al. (Noggle et al., 2011) succeeded to generate human pluri‐
potent cells by using SCNT. However, their study revealed that the classical SCNT consis‐
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tently leads to developmental arrest. The activated human oocytes develop to the blastocyst
stage only when the somatic cell genome is merely added and the oocyte genome is not re‐
moved. Human stem cells derived from these blastocysts contain both a haploid genome de‐
rived from the oocyte and a diploid somatic cell genome reprogrammed to a pluripotent
state (Noggle et al., 2011). However, the SCNT raises some ethical concerns regarding the
use of human eggs. It has also been reported that somatic cells could be reprogrammed by
fusion with ES cells (Do et al., 2006). These cells offer a good alternative to SCNT, especially
for studying the mechanisms of reprogramming, but are thought to be less interesting for
therapies due to the presence of the nuclei of stem cells in the hybrids and their instability.
Human ESC lines derived from parthenogenetic blastocysts obtained by artificial activation
of an oocyte have been obtained (Turovets et al., 2011). Their immune-matching advantage,
combined with the advantage of derivation from nonviable human embryos makes these
cells a good source for cell-based transplantation therapy. However, one of the most exciting
reports in reprogramming was the generation of iPSCs from terminally differentiated so‐
matic cells by transduction of four transcription factors (OCT4, SOX2, KLF4 and c-MYC) into
fibroblasts (Takahashi & Yamanaka, 2006).
By using various biological reagents (e.g. growth factors) (Schuldiner et al., 2000), ESCs can
be differentiated in the laboratory into a range of different cell types, including neurons,
glia, cardiomyocytes, islet beta cells, hepatocytes, hematopoietic progenitors and retinal pig‐
ment epithelium. The ESC ability to give rise to many different cell types is the reason that
makes them very good candidates for cellular therapies. Many of the diseases that place the
greatest burden on society are, at their root, diseases of cellular deficiency. Diabetes, stroke,
heart diseases, hematological and neurodegenerative disorders, blindness, spinal cord in‐
jury, osteoarthritis, and kidney failure all result from the absence of one or more populations
of cells that the body is unable to replace. Three basic methods have been developed to pro‐
mote differentiation of ESCs: (1) the formation of three-dimensional aggregates known as
embryoid bodies (EBs) (Itskovitz-Eldor et al., 2000), (2) the culture of ESCs as monolayers on
extracellular matrix proteins, and (3) the culture of ESCs directly on supportive stromal lay‐
ers (Kawasaki et al., 2000; Murry & Keller, 2008). However, the controlled differentiation of
ESCs is rather difficult to optimize due to the use of serum in the culture media and difficul‐
ty to select differentiated cells. In this chapter I will focus on the differentiation of ESCs into
the ectodermal lineage and on the two in 2012 ongoing clinical trials involving transplanta‐
tion of ESCs derivates into eye and spinal cord.
2. Treatment of eye diseases
Retinal degenerative diseases that target photoreceptors or the adjacent retinal pigment epi‐
thelium (RPE) affect millions of people worldwide. Age-related macular degeneration
(AMD) is a late-onset, complex disorder of the eye with a multi-factorial etiology in elderly
(Katta et al., 2009). Being the third leading cause of blindness worldwide, it accounts for
8.7% of blind persons globally. AMD results in progressive and irreversible loss of central
vision affecting the macula of the eye and involves the RPE, Bruch’s membrane (BM) and
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choriocapillaries (Katta et al., 2009). Other retinal diseases with limited conventional treat‐
ments include Stargardt's macular dystrophy (SMD) and retinitis pigmentosa (RP). SMD is
the most common early-onset macular degeneration disease, usually manifesting in people
between ages 10 to 20. Initially there is an abnormal deposit of lipofuscin (yellow–brown
granules of pigment that manifest with age) in the RPE. The RPE eventually degrades,
which leads to photoreceptor loss, causing a decrease in central vision (Rowland et al., 2012).
In attempts to develop cell-based therapies for blinding diseases, two different approaches
have to be distinguished. The first is a more direct approach of implanting appropriate reti‐
nal or RPE precursor cells, with the hope that they may integrate autonomously into the re‐
maining (and diseased) target tissue. The second strategy counts on a lesser degree of cell
autonomy within the diseased environment. Therefore, in this case, the bioengineer will first
reconstruct a piece of retina or RPE tissue in vitro, which then can be implanted into the le‐
sioned or diseased location (Layer et al., 2010). This approach is called tissue engineering.
Restoration of vision has focused up to now on transplantation of neural progenitor cells
(NPCs) and retinal pigmented epithelium (RPE) to the retina. The retinal pigment epitheli‐
um (RPE) is a monolayer of pigmented cells forming a part of the blood/retina barrier and
plays crucial roles in the maintenance and function of the retina and its photoreceptors
(Strauss, 2005). The apical membrane of the RPE is associated with the rod and cone photo‐
receptors of the retina. The basal side of the RPE faces Bruch’s membrane, thereby separat‐
ing the NR from the blood. The RPE absorbs light energy to increase visual sensitivity and
protect against photooxidation, transports nutrients and ions between the photoreceptors at
its apical surface and the choriocapillaries at its basal surface, phagocytoses photoreceptor
outer segments, according to a daily circadian cycle, to relieve the photoreceptors of light-
induced free radicals. The RPE secretes a variety of growth factors, such as the neuroprotec‐
tive-antiangiogenic pigment epithelium-derived factor (PEDF) which is released to the
neural retina, and the vasoprotective-angiogenic vascular endothelial growth factor (VEGF)
that is secreted to the choroid (Layer et al., 2010). With these diverse functions of the RPE it
is not surprising that dysfunction and loss of RPE leads to degeneration of photoreceptors
several diseases such as age-related macular degeneration (AMD), retinitis pigmentosa and
Stargardt´s disease.
2.1. Preclinical work
Cell transplantation is a novel therapeutic strategy to restore visual responses. Human em‐
bryonic stem cells (hESCs) may serve as an unlimited source of RPE cells and photorecep‐
tors for transplantation in different blinding conditions.
hESC studies have focused on the derivation of subsets of retinal cell populations (Meyer et
al., 2009), with emphasis on the production of either retinal progenitors (Banin et al., 2006;
Lamba et al., 2006), or more mature cells such as retinal pigment epithelium (RPE) (Kliman‐
skaya et al., 2004) or photoreceptors (Osakada et al., 2008).
Several groups have demonstrated that differentiating hESCs mimic the stepwise develop‐
ment of retinal cells in vivo (Meyer et al., 2009). Furthermore, hESCs appear to respond to
secreted morphogens in a manner predicted by studies of vertebrate neural induction and
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retinogenesis. In particular, blockade of bone morphogenetic protein and canonical Wnt sig‐
naling is known to be important for neural and retinal patterning, and many retinal differ‐
entiation protocols call for antagonists of one or both of these pathways to be included in the
culture medium (Gamm & Meyer, 2010). Furthermore, the differentiation toward neural and
further toward RPE fate is augmented by nicotinamide and Activin A (Idelson et al., 2009).
Several hESC lines actually generate neuroectodermal progenitors by spontaneous differen‐
tiation, without the addition of specific factors. RPE cells for example, were being isolated
from several spontaneously differentiating human ES cell lines (Klimanskaya et al., 2004). In
their hands (Klimanskaya et al., 2004), RPE-like differentiation occurred independently of
the presence of serum. RPE cells reliably appeared in cultures grown in the presence or ab‐
sence of FBS without significant variations in RPE number or time of appearance. The inde‐
pendence of this differentiation pathway on either coculture or extracellular matrix suggests
the involvement of other differentiation cues, such as potential autocrine factors produced
by differentiating hES cells. The hES-derived RPE-like cells expressed the same makers as
RPE cells, e.g. RPE65 protein and CRALBP (Alge et al., 2003; Klimanskaya et al., 2004).
So far, it has been shown that transplanted postmitotic photoreceptor precursors are able to
functionally integrate into the adult mouse neural retina. However, photoreceptors are neu‐
rons and they need to form synaptic connections in order to be functional. This makes the
cell therapy with photoreceptors more challenging when compared to RPE cells. Interesting‐
ly, a group from Japan (Eiraku et al., 2011) could obtain formation of a fully stratified neural
retina from by using a three dimensional ESCs culture system. The 3D organoids would
open up new avenues for the transplantation of artificial retinal tissue sheets, rather than
simple cell grafting.
2.2. Clinical trial
Until shortly, the most relevant clinical studies currently being conducted in patients with reti‐
nal degeneration were fetal retinal sheet transplants (Radtke et al., 2008). This strategy has its
basis on the fact that immature retinal sheet extends cell processes and forms synaptic connec‐
tions with the degenerate host retina. The underlying principle is that the inner retinal neurons
of the host remain intact and therefore only require synaptic connections with photoreceptors
for visual function to be restored. One big problem for the application of photoreceptor cell
transplantation is that an appropriate source of the precursor cells is required.
Advanced Cell Technology and Jules Stein Eye Institute at UCLA started two prospective
clinical studies to establish the safety and tolerability of subretinal transplantation of human
ESC-derived retinal pigment epithelium (RPE) in patients with Stargardt’s macular dystro‐
phy (clinical trial identifier-NCT01469832) and dry age-related macular degeneration (clini‐
cal trial identifier-NCT01344993) — the leading cause of blindness in the developed world
(Schwartz et al., 2012). The studies are in phase I/II, where only the safety and tolerability of
human ESC-derived RPE cells is assessed. The team of researchers from ACT and UCLA re‐
ported their preliminary work in two patients, one with AMD, the other with Stargardt’s
macular dystrophy, being the first to publish data on the use of human ESC-derived cells in
the clinic (Schwartz et al., 2012).
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One of the rationales behind using the eye for cell therapy is that the eye represents an immuno‐
privileged site. The failure of the immune system to elicit an immune response in this and other
such sites constitutes the hallmark of the immune privilege status (Hori et al., 2010). The re‐
markably successful field of corneal transplantation in clinical practice is undoubtedly associ‐
ated with corneal immune privilege. The subretinal space is protected by a blood–ocular
barrier and the ocular fluids contain a potpourri of immunosuppressive and immunoregulato‐
ry factors that suppress T-cell proliferation and secretion of proinflammatory cytokines and in‐
hibiting of both the cellular and humoral immune responses (Niederkorn, 2002).
Figure 1. Scheme of procedure for replacing damaged retinal pigment epithelium cells.
Embryonic Stem Cell Therapy – From Bench to Bed
http://dx.doi.org/10.5772/54368
401
Two patients  enrolled  in  the  clinical  trial  in  order  to  test  the  safety  of  such  cell  trans‐
plantations.  50  000  viable  RPE  cells  differentiated  from  the  hESC  line  MA09  (Kliman‐
skaya et al., 2006) by embryoid body formation were injected into the subretinal space of
each  patient’s  eye  (see  Fig.  1  for  schematic  overview).  The  cells  were  resuspended  in
phosphate buffered saline (PBS) and delivered in a region of pericentral macula that was
not completely lost to the disease. The authors thought that engraftment of the cells into
a  completely  atrophic  macula  was  unlikely  due  to  the  loss  of  Bruch’s  membrane.  The
primary outcome was positive: none of the concerns related to stem cell transplantations
as  teratomas,  rejection,  or  inflammation  were  observed.  The  transplanted  cells  attached
to Bruch’s membrane and persisted for the duration of the observation period. This was
however possible only in one of  the two patients.  Moreover,  clear functional  visual  im‐
provement was noted in the patient with Stargardt’s macular dystrophy.
This is the first peer reviewed study that uses human ESCs for cell therapy. Although their
report is preliminary, in only two patients, and with a short-term follow-up, the results are
impressive - especially considering the progressive nature of both diseases (Atala, 2012).
3. Treatment of spinal cord injury
More  than  a  decade  ago,  spinal-cord  injury  meant  confinement  to  a  wheelchair  and  a
lifetime of medical care. Published incidence rates for traumatic spinal-cord injury in the
USA range between 28 and 55 per million people, with about 10 000 new cases reported
every year. Causes include motor vehicle accidents (36–48%), violence (5–29%), falls (17–
21%), and recreational activities (7–16%) (McDonald & Sadowsky, 2002). The primary in‐
jury (the initial insult) is usually due to the mechanical trauma and includes traction and
compression  forces.  Neural  elements  are  compressed  by  fractured  and  displaced  bone
fragments, disc material, and ligaments and leads to injuries on both the central and pe‐
ripheral  nervous  systems.  Blood  vessels  are  damaged,  axons  disrupted  and  cell  mem‐
branes broken. Micro-haemorrhages occur within minutes in the central grey matter and
spread out over the next few hours. Within minutes, the spinal cord swells to occupy the
entire diameter of the spinal canal at the injury level.  Secondary ischaemia results when
cord swelling exceeds venous blood pressure.  The more destructive phase of  secondary
injury is,  however,  more responsible  for  cell  death and functional  deficits.  Hemorrhage,
edema, ischaemia, release of toxic chemicals from disrupted neural membranes, and elec‐
trolyte shifts trigger a secondary injury cascade that substantially compounds initial me‐
chanical  damage  by  harming  or  killing  neighbouring  cells  (McDonald  &  Sadowsky,
2002). Glutamate plays a key part in a highly disruptive process known as excitotoxicity.
It  was  demonstrated  that  glutamate,  released  during  injury,  damages  oligodendocytes
(Domercq et al., 2005). Oligodendrocytes express glutamate receptors as NMDA (Karadot‐
tir  et  al.,  2005)  and AMPA/kainate receptors (Domercq et  al.,  1999).  Up to now, the pri‐
mary  approach  in  treatment  is  limitation  of  secondary  injury  by  removal  of  damaging
bone, disc, and ligament fragments to decompress the swollen cord, followed by the ad‐
ministration of the steroid methyl-prednisolone (Bracken et al., 1990).
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There are many repair strategies in spinal cord injury, as prevention of cell death by anti-
glutamatergic drugs, promotion of axonal regeneration, compensation of the lost myelina‐
tion or cell replacement therapy (McDonald et al., 2002; McDonald & Sadowsky, 2002).
Different sources and types of cells, including stem/progenitor cells (embryonic stem cells,
neural progenitor cells, bone marrow mesenchymal cells) and non-stem cells (olfactory en‐
sheathing cells [OECs] and Schwann cells) have been, and/or are being tested in clinical tri‐
als for spinal cord injury (Fehlings & Vawda, 2011).
3.1. Differentiation to oligodendrocytes
As mentioned before in the case of spinal cord injury, diseases of the nervous system in‐
volve  proliferation of  astrocytes  and loss  of  oligodendrocytes  (OLN) and the  protective
myelin  sheath  they  produce.  Transplantation  of  oligodendrocyte  precursors  in  different
animals  systems  show  that  these  precursors  can  myelinate  axons  (Groves  et  al.,  1993).
Thus,  derivation of  oligodendrocytes from ESCs has been an important  goal  for  cell  re‐
placement therapy. The most common protocols involve an initial  differentiation step to
neural progenitors (Reubinoff et al.,  2001), followed by expansion, further differentiation,
and selection. These protocols follow the differentiation steps that take place in vivo. Dur‐
ing development, oligodendrocytes differentiate from precursors, which migrate and pro‐
liferate,  through immature oligodendrocytes,  which send out processes seeking axons to
myelinate, to mature myelinating oligodendrocytes that form myelin sheaths. The precur‐
sor cells are morphologically bipolar (when migrating) or stellate (after migration). These
initially  differentiate  into immature cells  that  put  out  processes seeking axons to myeli‐
nate,  and eventually form mature cells with parallel  processes myelinating up to 30 dif‐
ferent axons (Karadottir & Attwell, 2007).
Oligodendrocytes were first efficiently derived from mouse ESCs (Brustle et al., 1999), where
ESCs were aggregated to embryoid bodies and plated in a defined medium that favors the
survival of ES cell–derived neural precursors, followed by the expansion of progenitors in
culture medium containing FGF2 and EGF, and a switch to FGF2 and PDGF to yield bipo‐
tential glial progenitors (Brustle et al., 1999). These glial progenitors were transplanted into
the spinal cords of rats with a genetic deficiency in myelin production, yielding myelinated
fibers in the majority of animals (Learish et al., 1999). Human ESCs were first shown to dif‐
ferentiate into oligodendrocytes by Zhang et al., 2001, who used a similar strategy involving
FGF treatment followed by growth as neurospheres (Zhang et al., 2001). They reported the
differentiation of neural precursors into neurons, astrocytes and oligodendrocytes. Howev‐
er, no human oligodendrocytes were detected after transplantation of neural precursors into
the brains of newborn mice, although human neurons and some astrocytes were found to
have engrafted (Zhang et al., 2001).
The first detailed protocol for directed differentiation of oligodendrocytes from human ESCs
was published in 2005 and involved the induction of neural lineage by retinoic acid treat‐
ment, followed by expansion and selection in various media containing the differentiation
factors triiodothyroidin hormone, FGF2, EGF, and insulin (Nistor et al., 2005). After 42 days
of culture, the desired cells were found in yellow spheroids, which upon differentiation as
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low-density monolayers formed 85%–95% oligodendrocytes expressing typical markers as
GalC, RIP, and O4. Human embryonic stem cell (hESC)-derived oligodendrocytes were able
to integrate, differentiate and display a functional myelinating phenotype following trans‐
plantation into the shiverer mutant mouse (Nistor et al., 2005). Recently, other protocols
were developed for generation of oligodendrocytes from ESCs. The Neman and de Vellis
(Neman & de Vellis, 2012) laboratory has reported usage of defined serum-free media to‐
gether with morphogens, as retinoic acid and sonic hedgehog, to devise a new method to
derive a pure population of OLN from ESCs. These experiments show that human oligoden‐
drocytes can be generated in large numbers and used to restore myelination under some cir‐
cumstances in mice.
3.2. Clinical trial
In October 2010 the world's  first  clinical  trial  using human embryonic stem cells  began,
using  ESCs  converted  into  OLN  precursor  cells.  The  feasibility  of  the  treatment  was
proofed by a  wide  range of  pre-clinical  studies  that  have  shown that  human oligoden‐
drocyte progenitor cells  implanted after spinal cord injury in rodent models show func‐
tional  improvement  (Keirstead,  2005;  Keirstead et  al.,  2005;  Sharp et  al.,  2010).  Geron of
Menlo Park,  California,  is  the  biotech company that  received FDA approval  to  proceed
with clinical trials that transplant cells derived from embryonic stem cells into the spinal
cord (Alper,  2009).  This  company has  pioneered translational  research into  human ESC
therapies. The Geron trial (trial identification number NCT01217008), which was original‐
ly  approved by the  FDA,  but  then halted  due  to  concerns  of  abnormal  cyst  formation,
was reinitiated and approved for phase I  clinical  trials  in the U.S.  in October 2010.  The
trial  was  suspended following  news  that  animals  in  a  dose-escalation  study  developed
microscopic cysts in regenerating tissue sites. In november 2011 Geron announced that it
is dropping its entire program owing to financial concerns and started looking for part‐
ners  for  stem cell  treatments  and decided to  not  further  invest  in  the  clinical  trials  in‐
volving treatments with ESCs.
The trial was planned to involve treating ten patients who have suffered a complete thora‐
cic-level spinal cord injury in a phase 1 multicenter trial. The pioneering therapy is Geron's
'GRNOPC1 product', which contains hES cell–derived oligodendrocyte progenitor cells that
have demonstrated remyelinating and nerve growth–stimulating properties. In the human
SCI lesion site, it is hoped that OLN precursors will work as a "combination therapy" - phe‐
notypically replacing lost oligodendrocytes and hence remyelinating axons that have be‐
come demyelinated during injury, as well as secreting neurotrophic factors to establish a
repair environment in the lesion (Hatch et al., 2009). The ESCs were differentiated into OLN
precursors (Hatch et al., 2009) and one injection of 2 million GRNOPC1 cells was adminis‐
tered within 2 weeks in patients with thoracic spinal cord injury (Fig. 2). No serious adverse
effects were observed in the 2 patients enrolled, only one of the patients experienced some
side effects due to the immunosupression (Watson & Yeung, 2011). However, the data gen‐
erated by Geron for the FDA are not published and no preliminary report on the safety of
their product is available up to now.
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Figure 2. Scheme of procedure for treating spinal cord injury with human ESCs derived oligodendrocyte precursor cells.
4. Embryonic stem cells and tumorigenesis
The major safety concerns for the use of hESCs are related to the achievement of xenobi‐
otic-free culture conditions, avoidance of genetic abnormalities, development of good dif‐
ferentiation  and  selection  protocols,  and  the  avoidance  of  the  immune  rejection.
Moreover, the unlimited proliferative capacity of ESCs is a disadvantage in clinical appli‐
cations because this could cause tumor formation upon transplantation. When implanted
in an undifferentiated state, ESCs cause teratoma, a tumor type that consists of different
kinds of differentiated cells. Teratomas are encapsulated, usually benign tumors that can
occur naturally,  but  there  is  the fear,  based on some animal  studies,  that  some propor‐
tion of the cells derived from ESCs injected into the body could drift from their intended
developmental pathway. Teratoma formation was reported in various cases when mouse
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ESCs-derived cells like insulin producing islets (Fujikawa et al., 2005), ESC-derived cardi‐
omyocytes  (Cao  et  al.,  2006),  and  ESC-derived  neurons  (Schuldiner  et  al.,  2001)  were
transplanted into immunosuppressed mice even though there was successful engraftment
and functional improvement.  When undifferentiated human ESCs were injected into the
hind  limb  muscles  or  under  the  kidney  capsule  of  SCID  mice,  teratomas  were  readily
formed  after  8–12  weeks  (Richards  et  al.,  2002).  Evidence  of  tumor  formation  has  also
been observed in  differentiated hESC derivatives  transplanted in  vivo  (Roy et  al.,  2006).
In  another  study,  successful  hESC-derived  neuronal  engraftment  in  a  Parkinsonian  rat
model did not yield teratomas after 12 weeks (Ben-Hur et al.,  2004). When hESC-derived
osteocytes  or  cardiomyocytes  were  transplanted  into  the  bone  or  heart  of  severe  com‐
bined  immunodeficient  mice  (SCID),  there  was  also  no  teratoma  production  within  1
month after injection (Bielby et  al.,  2004;  Laflamme et  al.,  2007).  It  seems that the longer
hESCs are  differentiated in  vitro,  the  risk  of  teratoma formation appears  to  be  reduced.
Certain sites appear to favor the growth of teratomas, while others do not, confirming a
phenomenon already described that tumorigenesis of  ESCs is  site dependent.  For exam‐
ple the rate of teratoma formation with hESCs in immunodeficient mice was subcutane‐
ously  25–100%,  intratesticularly  60%,  intramuscularly  12.5%  and  under  the  kidney
capsule  100%  (Prokhorova  et  al.,  2009).  Furthermore,  tumor  formation  in  the  lung  and
thymus had the highest probability of teratoma formation while the pancreas was parti‐
ally  site-privileged  (Shih  et  al.,  2007).  Shih  et  al.  observed  an  aggressive  growth  of  tu‐
mors when human ESCs were injected into engrafted human fetal  tissues in SCID mice
(Shih et al., 2007).
The simplest way to slow or even eliminate the tumorigenicity of normal stem cells prior to
transplantation may be to take advantage of pluripotency by partially differentiating them
into progenitors. Therefore, a promising proposed method for making stem cell-based re‐
generative medicine therapies safer may seem paradoxical: to not transplant stem cells at all
into patients. The idea is to use the stem cells to produce progenitor or precursor cells of the
desired lineage and then transplant progenitors purified by sorting (Knoepfler, 2009). This
approach was presented in this chapter and is actually used in the clinical trial with oligo‐
dendrocyte progenitor cells. However, not only the embryonic stem cells, but also the im‐
planted precursor cells seem to form teratoma in some cases. A group of Israeli researchers
reported that a boy with ataxia telangiectasia who had received several fetal neural stem cell
transplants developed teratomas in his brain and spinal cord four years after treatment
(Amariglio et al., 2009). For this reason is very important to achieve a 100% pure population
of differentiated cells when using ESCs for cell therapy.
Currently, the only way to ensure that teratomas do not form is to differentiate the ESCs
in advance, enrich for the desired cell type, and screen for the presence of undifferentiat‐
ed cells. The elimination of undifferentiated hESCs may best be achieved by (1) destroy‐
ing  the  remaining  undifferentiated  hESCs  in  the  differentiated  tissue  population  with
specific agents or antibodies, (2) separating or removing the undifferentiated hESCs from
the differentiated cell  population, (3) eliminating pluripotent cells during the differentia‐
tion  process,  and (4)  inducing  further  differentiation  of  left-over  rogue  undifferentiated
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hESCs (Bongso et  al.,  2008).  It  is  also very important to develop very good and reliable
methods to detect residual ESCs contamination in ESCs derived cells prior to clinical ap‐
plication.  In their  review, Fong et  al.  (Fong et  al.,  2010)  presented some available meth‐
ods for the elimination of  undifferentiated ESCs.  These included single cell  propagation
with encapsulation, usage of density gradients,  MACS and FACS, usage of tumor privi‐
leged sites,  usage  of  antibodies  against  undifferentiated  ESCs,  prolonged differentiation
in vitro before transplantation or destruction of teratoma after engraftment. However, be‐
cause differentiation is not an on/off process, it is probably the best to use a combination
of these methods in order to do safe cell therapy.
5. Embryonic stem cells versus induced pluripotent stem cells in clinics
Induced pluripotent cells (iPS) are generated by re-engineering mature, fully differentiat‐
ed cells (e.g. human skin fibroblasts) by modifying the cells with a set of transgenes (Ta‐
kahashi  &  Yamanaka,  2006;  Takahashi  et  al.,  2007).  Induced  pluripotent  stem  cells,
created by turning back the developmental  clock on adult  tissues,  display similar  gene-
expression patterns to ESCs, and can produce various tissues in the human body. How‐
ever, iPS cells have a major advantage over ESCs; they can be obtained directly from the
individual that has to be treated. Thus, as a source of cells for therapy, they are able to
avoid the immunocompatibility issues. Furthermore, the utilization of these stem cells in
both clinical and basic research studies does not face ethical and political issues that oth‐
erwise surround the use of embryonic stem cells.
During the last years various studies reported the differentiation of iPS cells to various types
of cells in vitro and these cells were used for cellular therapy in various mouse models (Wer‐
nig et al., 2008; Saha & Jaenisch, 2009).
However,  before  bringing  these  cells  into  the  clinics,  their  safety  should  be  tested.  For
example, the initial enthusiasm related to bringing iPS cells into clinics dampened when
it  was  shown  that  these  cells  develop  teratoma  more  efficiently  than  ESCs  (Gutierrez-
Aranda et al., 2010). It was also shown that iPS retain the epigenetic memory of the cells
from which they are derived; this fact makes them to preferentially differentiate into the
cell  lineage  from which  they  came from.  Future  clinical  applications  will  demand new
techniques for generating factor-free iPS cells such as virus-free or DNA-free approaches
at  acceptable  efficiencies.  There  are  also  other  disadvantages  in  using  iPS  cells  in  the
clinics. Usually, they are made by integrating retroviruses into the cells as shuttle for the
reprogramming factors. This problem may be solved by transient gene transfer or by de‐
livering the  pluripotency factors  in  protein  form (Murry & Keller,  2008).  The  second is
that iPS cells are not an ‘‘off-the-shelf’’ product and would likely only be produced after
the patient becomes ill,  precluding their use in the acute phase of the disease (Murry &
Keller,  2008).  Quality  control  is  will  also  be  difficult  and expensive,  because  a  separate
batch of iPS cells would have to be made for each patient.
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6. Conclusion
There is no doubt that after the hurdles are overcome, hESC-derived cells have a promising
future for transplantation therapy given the versatility of these cells. It is very encouraging
to see that clinical trials involving the use of hESCs have begun, and that extensive efforts
are underway to efficiently, and safely differentiate hESCs into specific cell types.
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